Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 18/20 | 0.66 |
| ▸ | CA2 | P00918 | 4/20 | 0.66 |
| ▸ | CA9 | Q16790 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1258790 | 0.97 | STS (0.65) | STSCA2CA9 | |
| SCHEMBL1259424 | 0.86 | STS (0.62) | STSCA2CA9 | |
| SCHEMBL4202096 | 0.85 | STS (0.75) | STSCA2CA9 | |
| SCHEMBL4202099 | 0.85 | STS (0.75) | STSCA2CA9 | |
| SCHEMBL1259399 | 0.84 | STS (0.62) | STSCA2CA9 | |
| SCHEMBL1258813 | 0.84 | STS (0.68) | STSCA2CA9 | |
| SCHEMBL2856714 | 0.84 | ESR1 (0.64) | CA2CA9 | |
| SCHEMBL2856241 | 0.84 | STS (0.68) | STSCA2CA9 | |
| SCHEMBL4204963 | 0.84 | STS (0.49) | STSCA2CA9 | |
| SCHEMBL3383953 | 0.83 | ESR1 (0.49) | STSCA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1594884-B1 | ANTITUMORAL 18A-HOMOESTRA-1,3,5(10)-TRIEN-3-YL 2-SUBSTITUTED SULFAMATES | STERIX LTD (GB) | 2010-01-13 | — | — | EP | claimed |
| US-20060211670-A1 | Antitumoral18a-homoestra-1,3,5(10)-trien-3yl 2-substituted sulfamates | STERIX LIMITED (GB) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211670-A1 | Antitumoral18a-homoestra-1,3,5(10)-trien-3yl 2-substituted sulfamates | NR5A1, CYP19A1, SULT1E1 | STS 16/4885CA2 1454/4885CA9 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.